Indian market to grow 20% this year; France tries DTC campaign for generics;

@FiercePharma: Stada exec says board would entertain the right offer. Report | Follow @FiercePharma

 @AlisonBFierce: Manufacturers already shipped more than 128M doses of flu vaccine--nearly 95% of the 135M doses made this season. More | Follow @AlisonBFierce

> France is asking the European Medicines Agency to add labeling warnings to newer contraceptives over concerns of higher risks of blood clots. Story

> A report by Morgan Stanley says India's drug market could grow nearly 20% this year as early investments start to provide results. Item

> Canadian pharmacy chain Jean Coutu Group said sales of its generic drug line have lifted its quarterly profit 10%. Story

> Gilead Sciences ($GILD) is being criticized by HIV support groups for having moved prices up on a number of its most-used drugs. Story

Medical Device News

 @FierceMedDev: Bayer gains FDA nod for long-use IUD. Story | Follow @FierceMedDev

@MarkHFierce: A Swiss Dx company focused on nanotech brought in $3M in new Series A financing. Article | Follow @MarkHFierce

 @DamianFierce: $LLY's jumping back on the companion diagnostics bandwagon with a new Dako partnership. Report | Follow @DamianFierce

> Medtronic hunts for expanded pacer indication with large study. Story

> As of July 1, Malaysia mandates device product registration. Item

Biotech News

 @FierceBiotech: J&J's diabetes drug passes FDA panel test despite safety concerns. Story | Follow @FierceBiotech

@RyanMFierce: Another failure for tivantinib $ARQL. Ph2 in colon cancer after PhIII fiasco in lung cancer last year. | Follow @RyanMFierce

> GSK rests hopes on R&D pipeline after tough 2012. Article

> ArQule, Daiichi cough up another failure for lead cancer drug. Story

And Finally... A three-week direct-to-consumer campaign to boost confidence in generic drugs is kicking off in France where only about 25% of prescriptions are for generics, compared with about 80% in the U.S. Story

Suggested Articles

The FDA has raised questions about the manufacturing of Glenmark's new molecular entity Ryaltris, a nasal spray for seasonal allergic rhinitis.

Despite unconventional support from President Donald Trump, Johnson & Johnson’s Spravato didn’t win broad backing at the VA.

Months after trial deaths prompted the FDA to halt study enrollment for AbbVie’s Venclexta, the agency will give the drug another shot.